Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Elie Cousin, Emmanuel Oger, Jean-Hugues Dalle, Yves Bertrand, Sophie Pertuisel, Cecile Pochon, Claire Galambrun, Pauline Simon, Benedicte Bruno, Catherine Paillard, Pascale Schneider, Pierre Rohrlich, Régis Peffault de La Tour, Claire Freycon, Jean-Francois Eliaou, Gilbert Semana, Philippe Jonveaux, Severine Drunat, Pierre Bordigoni & Virginie Gandemer. (2020) Assessment of chimerism and immunomodulation to prevent post-transplantation relapse in childhood acute myeloblastic leukemia: is it the right approach?. Pediatric Hematology and Oncology 37:3, pages 259-268.
Read now
Read now
Chun-Hong Xie, Min Wei, Fei-Yan Yang, Fu-Zhen Wu, Lei Chen, Jian-Kun Wang, Qin Liu & Jin-Xiong Huang. (2018) Efficacy and safety of lenalidomide for the treatment of acute myeloid leukemia: a systematic review and meta-analysis. Cancer Management and Research 10, pages 3637-3648.
Read now
Read now
Belen Lopez-Millan, Rafael Diaz de la Guardia, Heleia Roca-Ho, Eduardo Anguita, Abul B. M. M. K. Islam, Damia Romero-Moya, Cristina Prieto, Francisco Gutierrez-Agüera, Jose Antonio Bejarano-Garcia, Jose Antonio Perez-Simon, Paula Costales, Montse Rovira, Pedro Marín, Silvia Menendez, Mar Iglesias, Jose Luis Fuster, Alvaro Urbano-Ispizua, Fernando Anjos-Afonso, Clara Bueno & Pablo Menendez. (2018) IMiDs mobilize acute myeloid leukemia blasts to peripheral blood through downregulation of CXCR4 but fail to potentiate AraC/Idarubicin activity in preclinical models of non del5q/5q- AML. OncoImmunology 7:9.
Read now
Read now
Articles from other publishers (9)
Pavlína Janovská, Emmanuel Normant, Hari Miskin & Vítězslav Bryja. (2020) Targeting Casein Kinase 1 (CK1) in Hematological Cancers. International Journal of Molecular Sciences 21:23, pages 9026.
Crossref
Crossref
Eva Leufven & Øystein Bruserud. (2019) Immunosuppression and Immunotargeted Therapy in Acute Myeloid Leukemia - The Potential Use of Checkpoint Inhibitors in Combination with Other Treatments. Current Medicinal Chemistry 26:28, pages 5244-5261.
Crossref
Crossref
Aude Le Roy, Thomas Prébet, Rémy Castellano, Armelle Goubard, Florence Riccardi, Cyril Fauriat, Samuel Granjeaud, Audrey Benyamine, Céline Castanier, Florence Orlanducci, Amira Ben Amara, Frédéric Pont, Jean-Jacques Fournié, Yves Collette, Jean-Louis Mege, Norbert Vey & Daniel Olive. (2018) Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities. Frontiers in Immunology 9.
Crossref
Crossref
P. Pallavi Madhusoodhan, William L. Carroll & Teena Bhatla. (2016) Progress and Prospects in Pediatric Leukemia. Current Problems in Pediatric and Adolescent Health Care 46:7, pages 229-241.
Crossref
Crossref
Qing-Yuan Wang, Hua Zhong, Fang-Yuan Chen, Min-Yue Zhang, Jia-Yi Cai & Ji-Hua Zhong. (2016) A preliminary study on epigenetic regulation of Acanthopanax senticosus in leukemia cell lines. Experimental Hematology 44:6, pages 466-473.
Crossref
Crossref
Elizabeth A. Griffiths, William E. Brady, Wei Tan, Carlos E. Vigil, James E. Thompson, Laurie A. Ford, Noelle M. Dickey, Heather L. Bashaw, Jill Sperrazza, Meir Wetzler & Eunice S. Wang. (2016) A phase I study of intermediate dose cytarabine in combination with lenalidomide in relapsed/refractory acute myeloid leukemia. Leukemia Research 43, pages 44-48.
Crossref
Crossref
Chindu Govindaraj, Mutsa Madondo, Ying Ying Kong, Peter Tan, Andrew Wei & Magdalena Plebanski. (2014) Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients. American Journal of Hematology 89:8, pages 795-802.
Crossref
Crossref
Kelly Faulk, Lia Gore & Todd Cooper. (2014) Overview of Therapy and Strategies for Optimizing Outcomes in De Novo Pediatric Acute Myeloid Leukemia. Pediatric Drugs 16:3, pages 213-227.
Crossref
Crossref
Peter H. Wiernik. (2014) Optimal Therapy for Adult Patients with Acute Myeloid Leukemia in First Complete Remission. Current Treatment Options in Oncology 15:2, pages 171-186.
Crossref
Crossref